



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/018,437-Conf. #4498
		Filing Date	June 3, 2002
		First Named Inventor	Uwe Zangemeister-Wittke
		Art Unit	1635
		Examiner Name	T. C. Gibbs
Total Number of Pages in This Submission		Attorney Docket Number	27656/37821

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MARSHALL, GERSTEIN & BORUN LLP		
Signature			
Printed name	Jeffrey S. Sharp		
Date	March 3, 2005	Reg. No.	31,879

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 3, 2005


Signature: (Jeffrey S. Sharp)



1635 *TM*

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date shown below.

Dated: March 3, 2005

Signature: 

Jeffrey S. Sharp

Docket No.: 27656/37821  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

**ZANGEMEISTER-WITTKE et al.**

Application No.: 10/018,437

Group Art Unit: 1635

Filed: June 3, 2002

Examiner: Terra C. Gibbs

For: **OLIGONUCLEOTIDE DERIVATIVES  
DIRECTED AGAINST HUMAN BCL-XL  
AND HUMAN BCL-2 mRNA**

**RESPONSE TO EXAMINER'S COMMUNICATION,  
RESTRICTION REQUIREMENT  
AND AMENDMENT UNDER 37 C.F.R. §1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is in response to a communication from the Examiner dated February 24, 2005 requesting correction of the response to the Office Action dated November 30, 2004, filed on December 30, 2004, in which claims 1-26 were subjected to a five-way restriction requirement. In response to the request, Applicants elect Group II (claim 2). Applicants also amend claims 3, 4, 7, 8 and 26 such that each of claims 3-18 now depend from elected claim 2 and specify below further restrictions as they were applied by the Examiner against Group I. The current status of all pending claims have been reviewed and addressed as indicated below.

**INTRODUCTORY COMMENTS**

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

**A Current Listing of the Claims** begins on Page 2 of this paper.

**Remarks** begin on Page 8 of this paper.